2H-Indazole Derivatives as Agents for the Treatment of Brain Tumors and Brain Metastases
2H-indazole derivatives address the permeability issue of CDK4/6 inhibitors by providing effective treatment for brain tumors and metastases through enhanced blood-brain barrier penetration, showing superior efficacy in preclinical models.
Patent Information
- Application Number
- JP2021544138
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-01-29
- Filing Date
- 2020-01-28
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2040-01-28
AI Technical Summary
Current CDK4/6 inhibitors lack favorable blood-brain barrier permeability, hindering their development as treatments for brain diseases such as brain tumors and metastases.
Development of 2H-indazole derivatives that act as potent and selective CDK4/6 inhibitors with good blood-brain barrier penetration, allowing for effective treatment of brain tumors and metastases.
The 2H-indazole derivatives demonstrate superior brain penetration and efficacy in treating brain tumors and metastases, as evidenced by significant tumor volume reduction in mouse models compared to existing CDK4/6 inhibitors.
Smart Images

Figure 0007588590000043 
Figure 0007588590000044 
Figure 0007588590000001
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application No. 62 / 798,220, filed January 29, 2019, the disclosure of which is incorporated herein by reference in its entirety. Technical Field The present application relates to methods of treating brain tumors and brain metastases using 2H-indazole derivatives and compositions thereof. [Background technology]
[0002] Cyclin-dependent kinases are a family of protein kinases that regulate cell division and proliferation. Cell cycle progression is controlled by cyclins and their associated cyclin-dependent kinases, such as CDK1-CDK4 and CDK6, while other CDKs, such as CDK7-CDK9, are important for transcription. CDKs that bind to cyclins form heterodimeric complexes that phosphorylate their substrates on serine and threonine residues, which initiates events required for transcription and progression through the cell cycle (Malumbres, et al., Trends Biochem. Sci. 2005, 30, 630-641). Because uncontrolled cell proliferation is a hallmark of cancer and most cancer cells exhibit deregulation of CDKs, inhibition of CDKs has emerged as a potential treatment for various cancers. Inhibitors with different degrees of selectivity for CDKs have been reported. Selective CDK4 / 6 inhibitors are currently considered a promising class of potential cancer therapeutics due to the essential role of CDK4 / 6 in regulating cell proliferation and the toxic effects associated with the inhibition of other CDKs.
[0003] Abemaciclib, palbociclib, and ribociclib have recently + / HER2 - It is a CDK4 / 6 inhibitor approved for the treatment of breast cancer. [ka] [ka]
[0004] However, neither of these agents demonstrates favorable blood-brain barrier (BBB) permeability in preclinical pharmacokinetic (PK) and efficacy models. See, e.g., Raub, TJ et al., Drug Metab. Dispos. 2015, 43, 1360-1371. Furthermore, both palbociclib and abemaciclib are p-glycoprotein (P-gp) substrates, a highly undesirable property for a potential CNS drug, This could hinder its development for brain diseases. .
[0005] Brain metastasis (or "secondary brain tumor") refers to cancer cells that spread to the brain from an original diseased organ in the body, which can occur in any cancer, but more commonly from lung, breast, colon, kidney, and melanoma. According to the literature, brain metastases occur in an estimated 24-45% of all cancer patients in the United States (see https: / / emedicine.medscape.com / article / 1157902-overview) and in 10-30% of adult cancer patients (see https: / / www.mayoclinic.org / diseases-conditions / brain-metastases / symptoms-causes / syc-20350136). Brain metastases exert pressure on the surrounding brain tissue, which can cause a variety of signs and symptoms, including severe pain. Treating brain metastases is important not only to help cancer patients live longer, but also to reduce pain and other symptoms and improve the patient's quality of life. Summary of the Invention [Problem to be solved by the invention]
[0006] Thus, there is a clear unmet medical need to develop CDK4 / 6 inhibitors with high BBB permeability. [Means for solving the problem]
[0007] Summary of the invention The present invention is based on the surprising discovery that the indazole compounds of formula (I) are potent and selective CDK4 / 6 inhibitors with good blood-brain barrier (BBB) permeability.Therefore, these compounds are useful therapeutic agents for the treatment or prevention of brain metastases from brain tumors and various other cancers.
[0008] In one embodiment, the present invention provides a method of treating a brain tumor or brain metastasis in a subject, comprising administering a therapeutically effective amount of a compound of formula (I): [ka] (I) [In the formula, R 1 is hydrogen, C 1 -C 8 Alkyl, C 3 -C 7 Cycloalkyl, R 6 C(O)- or R 7 O(CO)-; R 2 and R 3 are each independently hydrogen, C 1 -C 8 Alkyl, C 3 -C 7 Cycloalkyl, or C 3 -C 7 cycloalkylmethyl; R 4 is hydrogen, halogen, C 1 -C 8 Alkyl, or C 3 -C 7 is cycloalkyl; R 5 is hydrogen or a halogen; R 6 is hydrogen, C 1 -C 8 Alkyl or C 3 -C 7 is cycloalkyl; and R 7 is C1 -C 8 Alkyl or C 3 -C 7 is cycloalkyl; wherein any said alkyl or cycloalkyl is optionally substituted. or a pharma- ceutically acceptable salt, solvate or prodrug thereof.
[0009] In another aspect, the present invention provides the use of a compound of formula (I) in the manufacture of a medicament for the treatment of brain tumors or brain metastases associated with CDK4 and / or CDK6 activity.
[0010] Compound 1, N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-amine, is 1 is ethyl, and R 2 is isopropyl, R 3 is methyl, and R 4 is hydrogen, and R 5 is an example of a compound of formula (I) in which is fluoro. Compound 1 is a potent selective inhibitor of CDK4 / 6 and is useful for treating or preventing diseases, disorders, or medical conditions mediated by certain CDKs, particularly CDK4 and CDK6, such as various types of cancer and inflammation-related conditions. Brain tumors, such as glioblastoma, represent a therapeutic area in which CDK4 / 6 inhibitors are expected to have a high potential for efficacy. [ka] compound 1
[0011] In particular, the present invention provides methods for treating brain metastases of various cancers, including, but not limited to, breast cancer, lung cancer, particularly non-small cell lung cancer (NSCLC), colorectal cancer, prostate cancer, renal cancer, melanoma, mantle cell lymphoma (MCL), chronic myeloid leukemia (CML), acute myeloid leukemia (AML), and the like. [Brief description of the drawings]
[0012] [Figure 1] Figure 1 shows the efficacy of the abemaciclib / TMZ combination. Dosing: TMZ, QD x 5; 6mg / kg + abemaciclib, PO, QD x 21, 100mg / kg. [Diagram 2] Figure 1 shows the efficacy of the Compound 1 / TMZ combination. Dosing: TMZ: QD x 5; 6 mg / kg + Compound 1, PO, QD x 21, 100 mg / kg. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0013] Detailed Description of the Invention One embodiment of the present invention is a method of treating brain tumors or brain metastases from other cancers, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I): [ka] (I) [In the formula, R 1 is hydrogen, C 1 -C 8 Alkyl, C 3 -C 7 Cycloalkyl, R 6 C(O)- or R 7 O(CO)-; R 2 and R 3 are each independently hydrogen, C 1 -C 8 Alkyl, C 3 -C 7 Cycloalkyl, or C 3 -C 7 cycloalkylmethyl; R 4 is hydrogen, halogen, C 1 -C 8 Alkyl, or C 3 -C 7 is cycloalkyl; R 5 is hydrogen or halogen; R is C1 -C 8 Can be alkyl; R 6 is hydrogen, C 1 -C 8 Alkyl or C 3 -C 7 is cycloalkyl; and R 7 is C 1 -C 8 Alkyl or C 3 -C 7 is cycloalkyl; wherein any said alkyl or cycloalkyl is optionally substituted. or a pharma- ceutically acceptable salt, solvate or prodrug thereof.
[0014] In one embodiment, R 1 is hydrogen, methyl, ethyl, propyl, or isopropyl.
[0015] In another embodiment, R 2 is C 1 -C 6 Alkyl, C 3 -C 6 Cycloalkyl, or C 3 -C 6 It may be cycloalkylmethyl.
[0016] In another embodiment, R 2 is methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclopentyl, cyclopropylmethyl, or cyclopentylmethyl.
[0017] In another embodiment, R 3 is C 1 -C 6 Alkyl or C 3 -C 6 It may be a cycloalkyl.
[0018] In another embodiment, R 3is methyl, ethyl, propyl, isopropyl, or cyclopropyl.
[0019] In another embodiment, R 4 is hydrogen or a halogen.
[0020] In another embodiment, R 5 is hydrogen or fluoro.
[0021] In another embodiment, R 1 is methyl or ethyl; R 2 is isopropyl, cyclopropyl, cyclopropylmethyl, or cyclopentyl; R 3 is methyl or ethyl; R 4 is hydrogen or fluoro; and R 5 is sometimes preferably hydrogen or fluoro.
[0022] In another embodiment, the invention encompasses any combination of the embodiments described herein.
[0023] Preferably, the brain tumour or metastatic cancer being treated expresses CDK4 and / or CDK6.Preferably, the brain tumour is a glioblastoma.
[0024] Another aspect of the present invention is a method of treating brain tumors or brain metastases from other cancers, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the formula: [ka] or a pharmaceutically acceptable salt, solvate or prodrug thereof. Preferably, the brain tumor or metastatic cancer being treated expresses CDK4 and / or CDK6. Preferably, the brain tumor is a glioblastoma.
[0025] A further aspect of the present invention relates to a method for the treatment of brain tumors or brain metastases associated with CDK4 and / or CDK6 activity comprising administering to a patient of formula (I): [ka] (I) [In the formula, R 1 is hydrogen, C 1 -C 8 Alkyl, or C 3 -C 7 is cycloalkyl; R 2 and R 3 are each independently hydrogen, C 1 -C 8 Alkyl, C 3 -C 7 Cycloalkyl, or C 3 -C 7 cycloalkylmethyl; R 4 is hydrogen, halogen, C 1 -C 8 Alkyl, or C 3 -C 7 is cycloalkyl; and R 5 is hydrogen or a halogen. or a pharma- ceutically acceptable salt, solvate or prodrug thereof.
[0026] In some embodiments, R 1 is C 1 -C 6 It is an alkyl group. 1 is preferably methyl, ethyl, propyl, or isopropyl.
[0027] In some embodiments, R 2 is C 1 -C 6 Alkyl, C 3 -C 6 Cycloalkyl, or C 3 -C 6 Cycloalkylmethyl. R 2is preferably methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclopentyl, cyclopropylmethyl, or cyclopentylmethyl.
[0028] In some embodiments, R 3 is C 1 -C 6 Alkyl or C 3 -C 6 Cycloalkyl. R 3 is preferably methyl, ethyl, propyl, isopropyl, or cyclopropyl.
[0029] In some embodiments, R 4 is hydrogen or a halogen.
[0030] In some embodiments, R 5 is hydrogen or fluoro.
[0031] In some embodiments, R 1 is methyl or ethyl; R 2 is isopropyl, cyclopropyl, cyclopropylmethyl, or cyclopentyl; R 3 is methyl or ethyl; R 4 is hydrogen or fluoro; and R 5 may more preferably be hydrogen or fluoro.
[0032] In some preferred embodiments, the brain tumor associated with CDK4 and / or CDK6 activity is a brain metastasis of glioblastoma or another cancer.
[0033] Another aspect of the present invention relates to the manufacture of a medicament for the treatment of brain tumors or brain metastases associated with CDK4 and / or CDK6 activity. formula: [ka] or a pharma- ceutically acceptable salt, solvate or prodrug thereof. Preferably, the brain tumor is glioblastoma.
[0034] In any of the above embodiments, the cancers associated with CDK4 and / or CDK6 activity and causing brain metastasis include, but are not limited to, breast cancer, lung cancer (particularly non-small cell lung cancer (NSCLC)), colorectal cancer, prostate cancer, renal cancer, melanoma, mantle cell lymphoma (MCL), chronic myeloid leukemia (CML), acute myeloid leukemia (AML), and the like, and according to any of the embodiments disclosed herein, the method comprises administering a therapeutically effective amount of a compound to a cancer patient.
[0035] In a preferred embodiment, the methods relate to metastatic breast cancer.
[0036] In another preferred embodiment, the method relates to the treatment of metastatic lung cancer, in particular metastatic non-small cell lung cancer.
[0037] In some embodiments, the present invention provides methods of using the compounds disclosed herein in cancer patients for a prophylactic effect to prevent brain metastasis, i.e., the spread of cancer cells from the original affected organ.
[0038] In all embodiments, preferably the brain tumour or brain metastasis is associated with CDK activity, in particular CDK4 or CDK6 activity.
[0039] The present invention includes all possible combinations of any of the embodiments disclosed herein.
[0040] As used herein, unless otherwise noted, the term "alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups containing 1 to 8 carbons, preferably 1 to 6, and more preferably 1 to 4 carbons. The term includes, but is not limited to, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, and the like.
[0041] Unless otherwise noted, the term "alkylene" as used herein means a divalent saturated aliphatic radical derived from an alkane by the removal of two hydrogen atoms. Examples include methylene (-CH 2 -), ethylene (-CH 2 CH 2 -), propylene (-CH 2 CH 2 CH 2 -) but are not limited to these.
[0042] Unless otherwise noted, the term "cycloalkyl" as used herein alone or as part of another group includes saturated cyclic hydrocarbon radicals having 3 to 8, and sometimes preferably 3 to 6, carbons forming the ring. Examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0043] As used herein, "halo" or "halogen" means fluoro (F), chloro (Cl), bromo (Br), and iodo (I).
[0044] Additionally, in any of the embodiments disclosed herein, the alkyl, alkylene, cycloalkyl, and cycloalkoxymethyl groups each optionally contain one or more, preferably 1 to 3, and sometimes preferably 1 to 2, halogen, C 1 -C 4 Alkyl, OH, C 1 -C 4 It may be independently substituted with substituents independently selected from the group consisting of alkoxy, and CN.
[0045] When any group is said to be "optionally substituted," unless otherwise defined, it means that the group may be substituted or unsubstituted, provided that such substitution does not violate conventional bonding principles known to those of skill in the art. When the phrase "optionally substituted" is used before a list of groups, it means that each of the listed groups can be optionally substituted.
[0046] Those of skill in the art will understand that with respect to any molecule described as containing one or more substituents, only sterically practical and / or synthetically feasible compounds are meant to be included. Unless otherwise specified herein, when a variable moiety is optionally substituted or said to be substituted with a substituent, it is understood that this occurs by replacing a hydrogen covalently bonded to the variable moiety with one of these substituents.
[0047] The compounds of the present invention are generally recognized as organic bases that can react with acids, particularly pharma- ceutically acceptable acids, to form pharma- ceutically acceptable salts.
[0048] As used herein, the term "pharmaceutically acceptable salt" refers to a salt that is suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic reaction, etc., within the scope of sound medical judgment, and commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. See, for example, SM Berge et al., J. Pharm. Sci., 1977, 66, 1-19, which is incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of the present invention include those derived from suitable inorganic and organic acids. Examples of pharmaceutically acceptable non-toxic acid addition salts are salts of amino groups formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, or by using other methods used in the art, such as ion exchange. Other pharma- ceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentane propionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxyethanesulfonate, lanthanide, and cyclopentane. Examples of pharmaceutically acceptable salts include but are not limited to, carbohydrate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerianate, etc. Preferred pharmaceutically acceptable salts include hydrochloride salts.
[0049] The term "solvate" as used herein refers to a physical association of a compound of the present invention with a stoichiometric or non-stoichiometric amount of solvent molecules. For example, one molecule of the compound is associated with one or more, preferably 1-3, solvent molecules. It is also possible for multiple (e.g., 1.5 or 2) molecules of the compound to share one solvent molecule. This physical association may include hydrogen bonding. In certain instances, the solvate may be isolated as a crystalline solid. The solvent molecules in the solvate may be present in an ordered and / or disordered arrangement. Exemplary solvates include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates. Methods of solvation are generally known in the art.
[0050] The compounds of general formula (I) disclosed herein may themselves be in "prodrug" form, i.e., R 1 When is an acyl (i.e., RC(O)-) or ester (i.e., ROC(O)-) group, these "prodrugs" can be generated in vivo under physiological conditions from other "prodrugs." Thus, with respect to these disclosed compounds, the term "prodrug" as used herein means a derivative of the compound that can be converted in vivo to generate the parent compound, for example, by hydrolysis in blood. Common examples of prodrugs in the present invention include amide or phosphoramide forms of active amine compounds, such as those represented by formula (II): [ka] (II) [In the formula, R 6 is an acyl group (e.g., acetyl, propionyl, formyl, etc.) or a phosphoryl group [e.g., -P(=O)(OH) 2 or alternatively, R in the activated amino compound. 3 is hydrogen, the corresponding amide or phosphoramide compounds may serve as prodrugs. Such amide or phosphoramide prodrug compounds can be prepared according to conventional methods known in the art.
[0051] For use in therapy, a therapeutically effective amount of the compounds of the present invention, or a pharma- ceutically acceptable salt or solvate thereof, can be administered as the raw chemical, although it is possible to provide the active ingredient as a pharmaceutical composition. Thus, the present disclosure further provides pharmaceutical compositions comprising any compound of the present invention, or a pharma- ceutically acceptable salt or solvate thereof, and one or more, preferably one to three, pharma- cetically acceptable carriers, diluents, or other excipients. The carriers, diluents, or other excipients must be acceptable in the sense of being compatible with the other ingredients of the formulation and not harmful to the subject being treated.
[0052] As used herein, the term "pharmacologically acceptable" means those characteristics of compounds, materials, compositions, and / or dosage forms which, within the scope of sound medical judgment, are suitable for use in contact with the tissues of a patient and which are effective for their intended use without undue toxicity, irritation, allergic response, or other problem or complication commensurate with a reasonable benefit / risk ratio.
[0053] Pharmaceutical preparations may be provided in unit dosage forms containing a predetermined amount of active ingredient per unit dose. Typically, the pharmaceutical compositions of the present disclosure will be administered from once every 1-5 days to about 1-5 times per day, or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute treatment. The amount of active ingredient that can be combined with the carrier materials to produce a single dosage form will vary depending on the condition being treated, the severity of the condition, the time of administration, the route of administration, the rate of excretion of the compound used, the duration of treatment, as well as the age, sex, weight, and condition of the patient. Preferred unit dosage formulations are those containing a daily dose or sub-dose of the active ingredient, as recited hereinabove. Generally, treatment is initiated with small amounts that are substantially less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is obtained. In general, the compounds are most desirably administered at concentration levels that will generally provide effective results without causing substantial harmful or deleterious side effects.
[0054] When the compositions of the present disclosure include a combination of a compound of the present disclosure with one or more, preferably one or two, additional therapeutic or prophylactic agents, both the compound and the additional agents will typically be present at dosage levels that are about 10-150%, more preferably about 10-80%, of the dosage normally administered in a monotherapy regimen.
[0055] The pharmaceutical preparations can be adapted for administration by any suitable route, for example, oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual, or transdermal), vaginal, or parenteral (including subcutaneous, intradermal, intramuscular, intraarticular, intrasynovial, substernal, intrathecal, intralesional, intravenous, or intradermal injection or infusion). Such preparations can be prepared by any method known in the art of pharmacy, for example, by combining the active ingredient with a carrier or excipient. Oral administration or administration by injection is preferred.
[0056] Pharmaceutical formulations adapted for oral administration may be presented as discrete units such as capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or whips; or oil-in-water liquid emulsions or water-in-oil emulsions.
[0057] For example, for oral administration in the form of tablets or capsules, the active drug component can be combined with an oral, non-toxic, pharma- ceutically acceptable inert carrier, such as ethanol, glycerol, water, etc. Powders are prepared by grinding the compound to a suitable fine size and mixing with a similarly com- minuted pharmaceutical carrier, such as an edible carbohydrate, for example, starch or mannitol. Flavoring agents, preservatives, dispersing agents, and coloring agents can also be present.
[0058] Capsules are made by preparing a powder mixture as described above and filling formed gelatin sheaths. Glidants and lubricants such as colloidal silica, talc, magnesium stearate, calcium stearate, or solid polyethylene glycol can be added to the powder mixture before the filling operation. Disintegrants or solubilizers such as agar-agar, calcium carbonate, or sodium carbonate can also be added to improve the availability of the drug when the capsule is ingested.
[0059] Furthermore, suitable binders, lubricants, disintegrants, and coloring agents can also be incorporated into the mixture as needed. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, and the like. Lubricants used in these dosage forms include sodium oleate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methylcellulose, agar, bentonite, xanthan gum, and the like. Tablets are formulated, for example, by preparing a powder mixture, granulating or slugging, adding lubricants and disintegrants, and compressing into tablets. Powder mixtures are prepared by mixing the compound, suitably comminuted, with a diluent or base as described above, and optionally with a binder such as carboxymethylcellulose, alligates, gelatin, or polyvinylpyrrolidone, a solution retarder such as paraffin, an absorption enhancer such as a quaternary salt, and / or an absorbent such as bentonite, kaolin, or dicalcium phosphate. The powder mixture can be granulated by wetting it with a binder such as syrup, starch paste, acadia mucilage, or a solution of cellulose or polymeric materials, and forcing it through a screen. As an alternative to granulation, the powder mixture can be run through a tablet machine, resulting in imperfectly formed slugs being broken into granules. The granules can be lubricated by the addition of stearic acid, a stearate salt, talc, or mineral oil to prevent sticking to the tablet forming dies. The lubricated mixture is then compressed into tablets. The compounds of the present disclosure can also be combined with a free-flowing inert carrier and compressed into tablets directly without going through the granulation or slugging steps. A clear or opaque protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material, and a polish coating of wax can be provided. Dyes can be added to these coatings to distinguish different unit dosages.
[0060] Oral liquids such as solution, syrup and elixir can be prepared in the form of dosage unit, so that a given amount contains a predetermined amount of compound.Syrup can be prepared by dissolving compound in suitable flavored aqueous solution, while elixir is prepared by using non-toxic vehicle.Solubilizers and emulsifiers such as ethoxylated isostearyl alcohol and polyoxyethylene sorbitol ether, preservatives, flavor additives such as peppermint oil or natural sweeteners, or saccharin or other artificial sweeteners can also be added.
[0061] If desired, dosage unit formulations for oral administration can be microencapsulated. The formulations can also be prepared so as to prolong or sustain release, for example, by coating or embedding the particulate matter in polymers, waxes, and the like.
[0062] It will be understood that in addition to the ingredients particularly mentioned above, the formulations may include other agents conventional in the art having regard to the type of formulation in question; for example, those suitable for oral administration may include flavoring agents.
[0063] The term "subject" or "patient" includes both humans and other mammals, including, but not limited to, horses, dogs, cats, pigs, monkeys, etc., with humans being preferred.
[0064] The term "therapeutically effective amount" refers to the amount of a compound or composition that, when administered to a subject for treating a disease, is sufficient to effect such treatment of the disease. A "therapeutically effective amount" may vary depending on, among other things, the compound, the disease and its severity, as well as the age, weight, or other factors of the subject being treated. When applied to an individual active ingredient administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to the combined amount of the active ingredients that results in the therapeutic effect, whether administered in combination, serially, or simultaneously.
[0065] In some embodiments, the term "treat" or "treatment" refers to (i) inhibiting a disease, disorder, or condition, i.e., arresting its development; (ii) alleviating a disease, disorder, or condition, i.e., causing regression of a disease, disorder, and / or condition; or (iii) preventing a disease, disorder, or condition from occurring in a subject who may be predisposed to the disease, disorder, and / or condition but has not yet been diagnosed as having it. Thus, in some embodiments, "treat" or "treatment" refers to ameliorating a disease or disorder, which may include improving one or more physical parameters that may not be discernible by the subject being treated. In some embodiments, "treat" or "treatment" includes modulating a disease or disorder, either physically (e.g., stabilization of discernible symptoms) or physiologically (e.g., stabilization of physical parameters) or both. Furthermore, in some embodiments, "treat" or "treatment" includes delaying the onset of a disease or disorder.
[0066] An efficacy and comparison study of compound 1 and abemaciclib in combination with temozolomide (TMZ) against orthotopic U87MG-luc human glioblastoma in mice was conducted. In each study, TMZ was administered at 6 mg / kg PO, QD x 5, and compound 1 or abemaciclib was administered at 100 mg / kg PO. Tumor growth was observed by bioluminescence. The abemaciclib / TMZ combination showed tumor volume reduction until day 42, followed by regrowth on day 49 (Figure 1). In contrast, the compound 1 / TMZ combination showed significant tumor volume reduction on day 28 and sustained tumor volume reduction until day 63 (Figure 2). Considering the comparable in vitro potency of compound 1 and abemaciclib, the superior in vivo efficacy of compound 1 compared to abemaciclib in the glioblastoma model may be attributed to the more favorable BBB permeability profile of compound 1 versus abemaciclib. From a broader perspective, the significant differences between compound 1 and abemaciclib in brain disease models can be traced to their distinct molecular structures.
[0067] The main difference between the molecular structures of compound 1 and abemaciclib is that compound 1 contains a 2H-indazole nucleus, whereas abemaciclib contains a benzimidazole nucleus: [ka] versus [ka]
[0068] This structural difference surprisingly results in a significant difference in BBB permeability profile between the two compounds. Example 3 describes an in vivo mouse study in which the brain concentration of compound 1 was observed to be about 3 times higher than that of abemaciclib, and the brain / plasma (B / P) ratio of compound 1 was 1.43 compared to 0.43 for abemaciclib (see Tables 1 and 2). Additionally, and notably, compound 1 is not a P-gp substrate (see Example 2).
[0069] Table 1: Brain concentrations and B / P ratios of Compound 1 in mice po at 10 mg / kg. [Table 1]
[0070] Table 2: Abemaciclib brain concentrations and B / P ratios in mice administered 10 mg / kg po [Table 2]
[0071] Although not intended to be limiting, illustrative non-limiting examples of compounds that can be used in the present invention are listed in Table 3.
[0072] Table 3: Selected examples of compounds of formula (I) [Table 3]
Table 4
Table 5
Table 6
Table 7
Table 8
Table 9
Table 10
Table 11
Table 12
Table 13
Table 14
Table 15
Table 16
Table 17
Table 18
Table 19
Table 20
Table 21
[0073] Example 1: In vivo efficacy studies in mice material and method D-luciferin (Lot No. 0000204125) was obtained as a white powder from Promega and stored at -80°C in a box with a lid to minimize light exposure. Saline was added to the D-luciferin powder to create a clear yellow 15 mg / ml solution for in vivo imaging. D-luciferin was prepared immediately prior to each bioluminescence imaging session and stored on wet ice protected from light during use.
[0074] Temozolomide (parent 99.0%, MW 194 g / mol, FW 194 g / mol, purity 99%, C 6 H 6 N 6 O 2 , Lot No. S123705) was obtained as a fine pink powder from SelleckChem. Upon receipt, it was stored at -20°C protected from light. Compounds were formulated in a vehicle of sterile water. The dosing formulation was vortexed to form a clear, colorless solution with a pH value of 6.3. Dosing solutions were prepared weekly and stored at 4°C protected from light between treatments.
[0075] Compound 1 (92.8% parent, MW 489 g / mol, FW 525 g / mol, purity 99.7%, C 27 H 33 FN 8HCl) was stored protected from light at 4°C in a nitrogen-rich environment. The compound was formulated in a vehicle of 10% ethanol, 10% CREMOPHOR®, and 80% saline (0.9% NaCl). The dosing formulation was prepared by first warming all vehicle components in a water bath set at approximately 42°C. Ethanol was first added to a sterile dosing vial containing a pre-weighed amount of BPI-1178 powder. The mixture was then vortexed to ensure all powder was completely dissolved. CREMOPHOR® was then added to the solution and vortexed to mix. Finally, saline was added and the final mixture was vortexed to create a clear, colorless solution with a pH value of 5.7. Dosing solutions were prepared fresh each day.
[0076] Abemaciclib (parent 83.7%, MW 506 g / mol, FW 603 g / mol, purity 99.6%, C 27 H 32 F 2 N 8 H 3 CSO 3 H) was obtained from Beta Pharma as a white, flaky powder. Upon receipt, it was stored protected from light at 4°C in a nitrogen-rich environment. The compound was formulated in a vehicle of 10% ethanol, 10% CREMOPHOR®, and 80% saline (0.9% NaCl). The dosing formulation was prepared by first warming all vehicle components in a water bath set at approximately 42°C. Ethanol was first added to a pre-weighed sterile dosing vial containing abemaciclib. The mixture was then vortexed to ensure all powder was completely dissolved. CREMOPHOR® was then added to the solution and vortexed to mix. Finally, saline was added and the final mixture was vortexed to create a clear, colorless solution with a pH value of 4.0. The dosing solution was prepared fresh each day.
[0077] Animals and husbandry In this study, female Envigo nude mice (Hsd:Athymic Nude-Foxn1 nu) were used. Animals were 6-7 weeks old on experimental day 1. Animals were fed irradiated Harlan 2918.15 rodent chow and water ad libitum. Animals were housed in INNOVIVE® disposable ventilated cages with corncob bedding in a BIOBUBBLE® clean room, which supplied the bubble environment with HEPA-filtered air at 100 complete air changes per hour. All treatments, weight measurements, and tumor measurements were performed in the bubble environment. The environment was controlled at a temperature range of 70° ± 2°F and a humidity range of 30-70%.
[0078] All procedures were performed in accordance with all National Institutes of Health (NIH) laws, regulations, and guidelines and with approval from the Animal Care and Use Committee of Molecular Imaging, Inc. Molecular Imaging, Inc. is an AAALAC-accredited facility.
[0079] Example 1A: Cell Preparation MG-Luc cells were obtained from ATCC. They were cultured in Minimum Essential Medium (MEM) containing 1% 100 mM sodium pyruvate, 1% 100X NEAA (non-essential amino acids), Earle's Salt modified with 200 μg / mL G418 and supplemented with 10% non-heat-inactivated fetal bovine serum (FBS) and 1% 100X penicillin / streptomycin / L-glutamine (PSG). The growth environment was 37°C, 5% CO. 2The cells were maintained in a room temperature incubator at 4°C. When proliferation was complete, the cells were trypsinized using 0.25% trypsin-EDTA solution. After cell detachment, the trypsin was inactivated by dilution with complete growth medium and cell clumps were separated by pipetting. The cells were centrifuged at 200 rcf for 8 min at 4°C, the supernatant was aspirated and the pellet was resuspended in cold Dulbecco's Phosphate Buffered Saline (DPBS) by pipetting. An aliquot of the homogenous cell suspension was diluted with trypan blue solution and counted using a Luna automated cell counter. The cell suspension was centrifuged at 200 rcf for 8 min at 4°C. The supernatant was aspirated and the cell pellet was resuspended in cold serum-free medium to produce a final concentration of 1.0E+08 trypan excluded cells / ml. During transplantation, the cell suspension was kept on wet ice. After transplantation, an aliquot of the remaining cells was diluted with trypan blue solution and counted to determine cell viability after transplantation.
[0080] [Table 23]
[0081] Example 1B: Intracranial Implantation Test mice were implanted intracranially with 1.0E+06 cells per 10 μl on days 0, 1, and 2. For aseptic surgical implantation, mice were injected with 0.2 mg / kg buprenorphine and anesthetized using 2% isoflurane in air. Mice were then secured in a stereotaxic frame (ASI instruments, Inc.) using non-rupture ear bars. Ophthalmic ointment was applied to the eyes of the mice to prevent dryness during surgery. A recirculating 37 °C water heating pad was used to maintain the animal's body temperature during the implantation procedure.
[0082] Once in the stereotaxic frame, the skull was wiped alternately with chlorhexidine solution and 70% ethanol saturated wipes to disinfect the skin surface and prepare for incision. A 1 cm longitudinal incision was made in the center of the bregma of the skull using a #15 BD scalpel blade. The incision was retracted using small serrated hemostat forceps. A thin layer of connective tissue overlying the surface of the skull was removed using a dry cotton swab under light pressure. Bleeding vessels were cauterized to prevent bleeding. A 0.9 mm drill bit was then placed in the center of the bregma, moved 2 mm to the right of the coronal suture and 1 mm anterior, and lowered to score the surface of the skull using the stereotaxic electrode manipulator arm. The drill was removed from the stereotaxic frame and a burr hole was manually completed from the skull to the surface of the dura.
[0083] The cell suspension (stored on wet ice) was mixed thoroughly and drawn up into a 50 μl gas-tight Hamilton syringe. A standard 27 g needle was filled with the cell suspension to eliminate air pockets, and the luer tip of the syringe was inserted into the needle hub. The syringe was secured in a custom-made syringe holder (ASI Instruments, Inc.) and attached to a stereotaxic frame manipulator arm. The syringe needle was placed in the center of the burr hole and lowered until the beveled tip was flush with the underside of the skull at the surface of the dura. The needle was then lowered 3 mm into the brain and retracted 1 mm to form a "reservoir" for deposition of the cell suspension. Next, 10 μl of the cell suspension ((1x10 6 cells / mouse) were slowly injected into the brain tissue and any slight leakage (common in IC transplants) was absorbed with a dry cotton swab.
[0084] After injection, the needle was withdrawn and the burr hole was immediately sealed with bone wax to minimize loss of transplanted cells. The skull surface was then cleaned using alternating dry and 70% ethanol-saturated cotton swabs to remove foreign cells and to prevent extracranial tumor growth. Mice were removed from the stereotaxic frame and the incision was closed using stainless steel wound clips. Once the mice had regained consciousness and a supine position, they were returned to their cages. Mice were implanted from February 20 to 22, 2017.
[0085] Example 1C: Treatment All mice were classified into study groups based on bioluminescence imaging (BLI) estimates of tumor burden. Mice were allocated such that the mean tumor burden for all groups was within 10% of the overall mean tumor burden for the study population. Implantation occurred over a 3-day period, so day 0 was defined as the midpoint of implantation (February 21, 2017). Treatment was initiated on day 21 for all groups, regardless of the date of initial implantation.
[0086] Group 1: Vehicle control (10% EtOH, 10% CREMOPHOR®, 80% saline (0.9% NaCl)), 0.2 mL / 20 g, PO, QDx21 (days 21-41) Group 2: Temozolomide, 6 mg / kg, PO, QDx5 (days 21-25) Group 3: Compound 1, 100 mg / kg, PO, QDx21 (days 21-41) Group 4: Abemaciclib, 100 mg / kg, PO, QDx21 (days 21-41) Group 5: Temozolomide, 6 mg / kg, PO, QDx5 (days 21-25) + Compound 1, 100 mg / kg, PO, QDx21 (days 21-41) Group 6: temozolomide, 6 mg / kg, PO, QDx5 (days 21-25) + abemaciclib, 100 mg / kg, PO, QDx21 (days 21-41)
[0087] Example 1D: In vivo Bioluminescence Imaging (BLI) In vivo bioluminescence imaging (BLI) was performed using IVIS Spectrum (Caliper Life Sciences, Hopkinton, MA). Animals were imaged up to five at a time under approximately 1-2% isoflurane gas anesthesia. Each mouse was injected subcutaneously with 150 mg / kg (15 mg / ml) D-luciferin and imaged in prone position 10 min after injection. Large binning of the CCD chip was used and exposure times were adjusted (2 s to 2 min) to obtain at least several hundred counts per image and avoid saturation of the CCD chip. BLI images were collected on days 21, 28, 35, 42, 49, 56, and 64.
[0088] Images were analyzed using MatlabR2015a software. Primary brain fixed-volume ROIs were placed on prone images of individual animals to estimate brain tumor burden. Total flux (photons / sec) was calculated and exported for all ROIs to facilitate analysis between groups.
[0089] Example 1E: Evaluation of Side Effects All animals were observed for clinical signs at least once daily. Animals were weighed on each day of treatment. Individual body weights were recorded three times per week.
[0090] Treatment-related weight loss of more than 20% is generally considered unacceptably toxic. This study stated that a dose level was acceptable if the treatment-related weight loss (during treatment and for 2 weeks after treatment) was less than 20% and the mortality rate during this period in the absence of lethal tumor burden was 10% or less.
[0091] Upon death or euthanasia, all animals were necropsied to provide a general assessment of potential causes of death and target organs of probable toxicity. The presence or absence of metastases was also noted. Signs of clinical concern and gross observations of necropsy findings were recorded, and individual and group toxicity findings were summarized.
[0092] Example 2: Cell permeability studies of compound 1 summary [Table 24] The test specimens are Lucifer Yellow single layer integrity test standards (≦0.8×10 -6 Passed the test (cm / s).
[0093] the purpose The aim of this study was to determine the P-gp substrate potential of one test article using MDR1-MDCK monolayers.
[0094] Experimental procedure MDR1-MDCK cell monolayers were grown to confluence on collagen-coated microporous membranes in 12-well assay plates. Plate details and their qualifications are shown below. The permeability assay buffer was Hanks' Balanced Salt Solution (HBSS) pH 7.4 containing 10 mM HEPES and 15 mM glucose. The buffer in the receiver chamber also contained 1% bovine serum albumin. The concentration of the dosing solution was 5 μM test article + / - 1 μM valspodar in assay buffer. Cells were first pre-incubated for 30 minutes with HBSS containing + / - 1 μM valspodar. Cell monolayers were dosed apically (A-to-B) or basolaterally (B-to-A) and incubated at 4°C for 30 min in a humidified incubator with 5% CO 2 The cells were incubated at 37°C for 120 min. Samples were taken from the donor and receiver chambers at 120 min. Each measurement was performed in duplicate. Lucifer Yellow flux was also measured after the experiment for each monolayer to ensure that no damage was done to the cell monolayer during the flux period. All samples were analyzed by LC-MS MS using electrospray ionization. The analytical conditions are outlined in Appendix 1. Apparent membrane permeability (P app ) and % recovery was calculated as follows: P app =(dC r / dt) × V r / (A×C A ) (1) Recovery % = 100 × ((Vr ×C r final )+(V d ×C d final )) / (V d ×C N ) (2) Where: dC r / dt is the slope of the cumulative concentration in the receiver compartment versus time (μM s -1 ); V r is the volume of the receiver compartment (cm 3 ) is; V d is the volume of the donor compartment (cm 3 ) is; A is the area of the insert (1.13 cm for 12 wells) 2 ) is; C A is the mean of the nominal administered concentration and the measured 120 min donor concentration (μM); C N is the nominal concentration of the dosing solution (μM); C r final is the cumulative receiver concentration (μM) at the end of the incubation period; C d final is the concentration of donor (μM) at the end of the incubation period.
[0095] The discharge ratio (ER) is P app (B-to-A) / P app It is defined as (A-to-B).
[0096] Cell batch quality control results [Table 25]
[0097] Experimental Results [Table 26]
[0098] P-gp substrate classification criteria: ER ≧ 2.0 50% or more decrease without valspodar and with valspodar: positive ER ≥ 2.0 Without valspodar and with valspodar, <50% decrease: negative ER < 2.0 with or without valspodar: negative Based on the above results, compound 1 is not a substrate for P-gp.
[0099] Analysis method Liquid chromatography Column: Waters ACQUITY UPLC® BEH Phenyl 30×2.1 mm, 1.7 μm MP buffer: 25 mM ammonium formate buffer, pH 3.5 Aqueous reservoir (A): 90% water, 10% buffer solution Organic reservoir (B): 90% acetonitrile, 10% buffer Flow rate: 0.7 mL / min Gradient Program: [Table 27] Total Run Time: 1.0 min Autosampler: Injection volume 5 μL Wash 1: Water / methanol / 2-propanol: 1 / 1 / 1; containing 0.2% formic acid Wash 2: 0.1% formic acid solution
[0100] mass spectrometry Equipment: PE SCIEX API 4000 Interface: Turbo Ion Spray Mode: Multiple reaction monitoring Method: 1.0 minute duration setting: [Table 28] TEM:500;CAD:7;CUR:30;GS1:50;GS2:50
[0101] Example 3: Brain concentrations and brain / plasma ratios in mice Mice were administered 10 mg / kg po. As shown in Tables 1 and 2, the brain concentration of compound 1 was approximately three times higher than that of abemaciclib, and the brain / plasma (B / P) ratio of compound 1 was 1.43 compared to only 0.43 for abemaciclib.
[0102] As disclosed herein, several ranges of values are provided. Unless the context clearly dictates otherwise, it is understood that each intervening value, to the tenth of the unit of the lower limit, is also specifically disclosed between the upper and lower limits of that range. Each smaller range between a stated value or intervening value in a stated range and any other stated or intervening value in that stated range is included in the invention. The upper and lower limits of these smaller ranges may be independently included or excluded in the range, and each range in which either, neither, or both limits are included in the smaller range is also included in the invention, subject to the specifically excluded limitations in the stated range. If a stated range includes one or both of the limits, then ranges excluding either or both of those included limits are also included in the invention. The term "about" generally includes up to ±10% of the stated number. For example, "about 10%" may indicate a range of 9% to 11%, and "about 20" may mean 18 to 22. Preferably, "about" includes up to ±6% of the stated value. Alternatively, "about" includes up to ±5% of the indicated value. Other meanings of "about" may be apparent from the context, such as rounding, so that, for example, "about 1" can also mean from 0.5 to 1.4.
[0103] All publications cited herein are incorporated by reference in their entirety for all purposes. It should be understood that the embodiments described herein should be considered as examples only, without limiting the scope of the present invention. The description of features or aspects within each embodiment should generally be considered applicable to other similar features or aspects in other embodiments.
[0104] While several embodiments are described in the above examples, it will be understood by those skilled in the art that various changes in form and details can be made therein without departing from the true spirit and scope of the disclosure as defined by the following claims.
Claims
1. In the manufacture of a medicament for the treatment of brain metastases from another cancer, or for the prevention of brain metastases in a subject having the other cancer, wherein the cancer is associated with CDK4 and / or CDK6 activity, a compound of the formula: 【Chemistry 1】 or 【Chemistry 2】 or a pharma- ceutically acceptable salt, or solvate thereof.
2. The compound is 【Chemistry 3】 The use according to claim 1,
3. 3. The use according to claim 1 or 2, wherein the compound or a pharma- ceutically acceptable salt thereof is used in conjunction with a second therapeutic agent in the manufacture of a medicament.
4. The use of claim 3, wherein the second therapeutic agent is another CDK inhibitor, a HER2 inhibitor, an mTOR inhibitor, or an EGFR inhibitor.
5. 5. The use according to any one of claims 1 to 4, wherein the other cancer is selected from the group consisting of breast cancer, lung cancer, colorectal cancer, prostate cancer, renal cancer, melanoma, mantle cell lymphoma (MCL), chronic myeloid leukemia (CML), and acute myeloid leukemia (AML).
6. The use described in claim 5, wherein the lung cancer is non-small cell lung cancer (NSCLC).
Citation Information
Patent Citations
2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and their therapeutic use
JP2017522390A
